Stanford Cancer Institute

点击翻译按钮获取中文摘要

PROJECT SUMMARY – OVERALL The Stanford Cancer Institute (SCI) is an NCI-Designated Comprehensive Cancer Center that integrates key strengths in cancer biology, immunology, genetics, population sciences and clinical oncology with expertise in imaging, engineering and technology development. The translation of basic science discoveries through clinical trials and collaborative team science is a distinguishing feature of the SCI. The SCI has 300 members and includes faculty from 32 Departments and from three Schools (Medicine, Engineering, and Humanities and Sciences) within Stanford University. Seven programs (Cancer Biology and Cancer Stem Cells, Cancer Imaging and Early Detection, Cancer Immunotherapy, Cancer Therapeutics, Hematologic Malignancies, Population Sciences, and Radiation Biology) address basic, translational, clinical, and population-based components of cancer research and are supported by 11 shared resources (Animal Tumor Models, Biomedical Informatics, Bioscience Screening, Biostatistics, Cancer Imaging, Cell Science Imaging, Flow Cytometry, Genomics, Human Immune Monitoring, Proteomics, and Tissue Procurement). With a current NCI funding base of $41.9 million, $33 million in other cancer-related NIH support, $16.4 million in other peer-reviewed cancer-relevant funding and $91.3 million in total peer reviewed funds, the SCI is fulfilling its mission to translate Stanford discoveries into improving the diagnosis, treatment, and outcomes of cancer patients and to better understand cancer etiologies among diverse populations in the Bay Area and beyond. SCI has made major investments in Population Sciences, including the recruitment of a new Associate Director for Population Sciences and the formation of a new Department of Epidemiology and Population Health. We have brought important focus to our catchment area and to health equity through the recruitment of a new Associate Director for Community Outreach and Engagement and the formation of a new SCI Office of Cancer Health Equity and Community Engagement. SCI has developed a highly successful clinical and translational effort in CAR-T therapies bringing new treatments to our patients. Finally, SCI has begun a major initiative in cancer drug discovery uniting cancer scientists, cancer physicians, chemists and engineers across the Stanford campus in their efforts to develop new cancer therapeutics. The SCI, under the new leadership of Steven Artandi, MD, PhD, is requesting CCSG support from the NCI for its critical activities, including in Community Outreach and Engagement, Shared Resources, Cancer Research Training and Education Coordination, Clinical Protocol and Data Management, Protocol Review and Monitoring, Program Leadership, Administration, and Developmental Funds. With new and talented additions to the senior leadership, many new recruitments, and highly effective collaborative interactions, the SCI is poised to further accelerate its contributions to cancer research in the next funding period.